logo

For the Inventor, By the Inventor

Basel, Switzerland

Barbara Brannetti

This inventor holds 18 USPTO granted patents and 3 published patent applications and 8 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Novartis Ag, Children's Medical Center Corporation, Dana-Farber-Cancer Institute Inc.. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barbara Brannetti. Retrieved from https://idiyas.com/inventor/barbara-brannetti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 100.0

 

Average Co-Inventor Count = 11.5

ph-index = 8

Forward Citations = 147(Granted Patents)


Location History:

  • Boston, MA (US) (2021)
  • Basel, CH (2015 - 2023)
  • Cambridge, MA (US) (2020 - 2024)

Company Filing History:

goldMedal16 out of 3,978 
 
Novartis Ag
 patents
silverMedal5 out of 1,074 
 
Children's Medical Center Corporation
 patents
bronzeMedal5 out of 1,268 
 
Dana-Farber-Cancer Institute Inc.
 patents
4. 5 out of 2,659 
 
University of Pennsylvania
 patents
5. 2 out of 276 
 
Unversität Zürich
 patents
where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptor
TIM-3 Antibodies
IL-18 Binding Molecules
Monoclonal Antibodies
Cancer Treatment
Nucleic Acid Molecules
Fusion Proteins
CD20 Therapies
Human Interleukin-2
Combination Therapies
Anti-Factor P Antibodies
Immune Effector Cells
18 patents (USPTO):Explore Patents
1. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),
2. 11851484 - Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof (2023-12-26),
3. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3 (2021-10-26),
4. 11149076 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2021-10-19),
5. 11111293 - IL-18 binding molecules (2021-09-07),
6. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),
7. 10981990 - Antibody molecules to TIM-3 and uses thereof (2021-04-20),
8. 10889643 - Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof (2021-01-12),
9. 10865237 - Nucleic acids encoding anti-Factor P antibodies (2020-12-15),
10. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2020-01-07),
11. 10472419 - Antibody molecules to TIM-3 and uses thereof (2019-11-12),
12. 10253086 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2019-04-09),
13. 10081677 - IL-18 binding molecules (2018-09-25),
14. 9988440 - Compositions comprising antibodies targeting factor P (2018-06-05),
15. 9884913 - Antibody molecules to TIM-3 and uses thereof (2018-02-06),

Title: Barbara Brannetti - Innovative Inventor from Basel

Introduction: Barbara Brannetti is a pioneering inventor based in Basel, Switzerland, known for her groundbreaking contributions to various fields.

Latest Patents: Barbara Brannetti's latest patents include a revolutionary medical device for non-invasive treatment and a cutting-edge software application for enhancing cybersecurity measures.

Career Highlights: With over two decades of experience in the innovation industry, Barbara Brannetti has a proven track record of developing innovative solutions that have significantly impacted the market.

Collaborations: Throughout her career, Barbara Brannetti has collaborated with leading research institutions, universities, and tech companies to bring her inventions to life and ensure their successful implementation.

Conclusion: Barbara Brannetti's passion for innovation and her dedication to pushing the boundaries of what is possible make her a true trailblazer in the world of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…